查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572200

BREO Ellipta 製药市场：按疾病、成分、最终用户、分销管道划分 - 2025-2030 年全球预测

BREO Ellipta Drugs Market by Disease Condition (Asthma, COPD), Component (Corticosteroid (ICS), Long-Acting Beta2-Adrenergic Agonist), End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

BREO Ellipta 製药市场 2023 年估值为 30.5 亿美元，预计到 2024 年将达到 31.8 亿美元，复合年增长率为 4.53%，到 2030 年将达到 41.6 亿美元。

BREO Ellipta 药物市场主要用于治疗慢性阻塞性肺病(COPD) 和气喘，这是由人口老化加剧、呼吸系统疾病盛行率上升以及早期诊断和治疗意识不断提高所推动的。这些药物是Fluticasone和Vilanterol的联合治疗，旨在改善肺功能并减少病情加重。对 BREO Ellipta 药物的需求源于对有效、易于使用、长效呼吸治疗的需求不断增长。主要用途是用于慢性阻塞性肺病和气喘的症状管理，最终用途集中在医院、诊所和居家医疗机构。促进该市场成长的主要因素包括给药系统的技术进步、支持性的政府法规以及越来越容易患呼吸道疾病的老年人口。最近的潜在商机在于利用远端医疗来扩大儿科医学和远端患者监护的应用。向医疗需求未被满足的新兴市场扩张也带来了新的商机。然而，市场面临一些限制因素，例如治疗成本高、皮质类固醇相关的副作用以及学名药的竞争，这些可能会抑製成长。此外，严格的法规环境和临床试验要求延长了上市时间。创新和研发领域包括提高联合治疗的功效、开发以患者为中心的吸入器以及整合数位健康技术以提高依从性和结果。了解生物相似药领域、投资于降低製造成本的策略以及收购本地企业可以进一步提高您的市场占有率。 BREO Ellipta 市场是一个适度细分且竞争激烈的市场，重点放在研发活动上，以在不断发展的製药领域保持竞争力。透过监控监管趋势并建立强大的分销网络，公司可以优化其市场地位并利用现有的成长机会实现显着成长。

主要市场统计
基准年[2023] 30.5亿美元
预测年份 [2024] 31.8亿美元
预测年份 [2030] 41.6亿美元
复合年增长率（%） 4.53%

市场动态：揭示快速发展的 BREO Ellipta 製药市场的关键市场洞察

BREO Ellipta 供需的动态交互作用正在改变药品市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性呼吸道疾病盛行率上升
    • 增强的吸入器技术可提高剂量准确性和患者舒适度
    • 改善新兴市场的医疗保健基础设施和药品的获取
  • 市场限制因素
    • 副作用和长期安全问题
  • 市场机会
    • 透过与医疗机构建立伙伴关係，建立医疗保健专业人员对 Breo Ellipta 的信任
    • 开发包括 Breo Ellipta 在内的联合治疗，以提高患者的依从性
  • 市场挑战
    • 复杂的法规环境因国家而异

波特五力：驾驭 BREO Ellipta 药品市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 BREO Ellipta 製药市场的外部影响

外部宏观环境因素在塑造 BREO Ellipta 製药市场的业绩动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 BREO Ellipta 药品市场的竞争状况

对 BREO Ellipta 製药市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 BREO Ellipta 供应商製药市场绩效评估

FPNV 定位矩阵是评估 BREO Ellipta Pharmaceuticals 市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 BREO Ellipta 药品市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对 BREO Ellipta Pharmaceuticals 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性呼吸道疾病盛行率上升
      • 吸入器技术的增强提高了剂量准确性和患者舒适度
      • 改善新兴市场的医疗保健基础设施和药品的获取
    • 抑制因素
      • 副作用和长期安全问题
    • 机会
      • 与医疗机构建立伙伴关係并培养医疗工作者对 BREO Ellipta 的信任
      • 开发包括 BREO Ellipta 在内的联合治疗，以提高患者的依从性
    • 任务
      • 不同国家的法规环境变得更加复杂和多样化。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 BREO Ellipta 药品市场（依疾病状况）

  • 气喘
  • 慢性阻塞性肺病

第 7 章 BREO Ellipta 製药市场：按组成部分

  • 皮质类固醇 (ICS)
  • 长效β2肾上腺素促效剂

第 8 章 BREO Ellipta 製药市场：依最终用户分类

  • 诊所
  • 家庭护理设置
  • 医院

第 9 章 BREO Ellipta 製药市场：按分销管道

  • 网上销售
  • 药局

第10章 BREO Ellipta美洲製药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 BREO Ellipta 亚太地区药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲的 BREO Ellipta 製药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Iconovo 吸入式 GLP-1 受体促效剂的开发选择
    • FDA 将气喘药物 Breo Ellipta 的核准扩大到 5 至 17 岁儿童
  • 战略分析和建议
Product Code: MRR-81515600A1FD

The BREO Ellipta Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.18 billion in 2024, and is projected to grow at a CAGR of 4.53%, to USD 4.16 billion by 2030.

The market for BREO Ellipta drugs, utilized primarily in treating chronic obstructive pulmonary disease (COPD) and asthma, is driven by a growing aging population, rising prevalence of respiratory ailments, and heightened awareness regarding early diagnosis and treatment. These medications provide a combination therapy approach of fluticasone and vilanterol, aimed at improving lung function and reducing exacerbations. The necessity for BREO Ellipta drugs stems from the increasing demand for effective, easy-to-use, and long-acting respiratory treatments. The major applications include symptom management in COPD and asthma, whereas end-use is concentrated in hospitals, clinics, and homecare settings. Key factors contributing to the growth of this market include technological advancements in drug delivery systems, supportive government regulations, and an expanding geriatric population more susceptible to respiratory diseases. Recent potential opportunities lie in extending application to pediatric care and exploiting telemedicine for remote patient monitoring. Expansion into emerging markets with unmet medical needs presents another opportunity. However, the market faces limiting factors, such as high treatment costs, side effects associated with corticosteroids, and competition from generic drug alternatives, which may restrain growth. Additionally, stringent regulatory environments and the essential requirement for clinical trials prolong market entry timelines. Areas for innovation and research prominently involve enhancing the efficacy of combination therapies, developing patient-centric inhalers, and integrating digital health technologies to improve compliance and outcomes. Understanding the biosimilars landscape, investing in strategies to reduce production costs, and acquisitions of local players can further bolster market presence. The nature of the BREO Ellipta market is moderately fragmented and competitive, emphasizing research and development activities to maintain a competitive edge in the ever-evolving pharmaceuticals landscape. By navigating regulatory pathways and building robust distribution networks, businesses can optimize their market position and leverage existing opportunities for substantial growth.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.18 billion
Forecast Year [2030] USD 4.16 billion
CAGR (%) 4.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving BREO Ellipta Drugs Market

The BREO Ellipta Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic respiratory diseases
    • Enhancements in inhaler technology to improve dosing accuracy and patient comfort
    • Improving healthcare infrastructure and access to medications in emerging markets
  • Market Restraints
    • Adverse side effects and long-term safety concerns
  • Market Opportunities
    • Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
    • Development of combination therapies involving BREO ellipta for enhanced patient compliance
  • Market Challenges
    • Complex and varying regulatory environments across different countries

Porter's Five Forces: A Strategic Tool for Navigating the BREO Ellipta Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the BREO Ellipta Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the BREO Ellipta Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the BREO Ellipta Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the BREO Ellipta Drugs Market

A detailed market share analysis in the BREO Ellipta Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the BREO Ellipta Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the BREO Ellipta Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the BREO Ellipta Drugs Market

A strategic analysis of the BREO Ellipta Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the BREO Ellipta Drugs Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Orion Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the BREO Ellipta Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Condition, market is studied across Asthma and COPD.
  • Based on Component, market is studied across Corticosteroid (ICS) and Long-Acting Beta2-Adrenergic Agonist.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Distribution Channel, market is studied across Online Sales and Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic respiratory diseases
      • 5.1.1.2. Enhancements in inhaler technology to improve dosing accuracy and patient comfort
      • 5.1.1.3. Improving healthcare infrastructure and access to medications in emerging markets
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse side effects and long-term safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
      • 5.1.3.2. Development of combination therapies involving BREO ellipta for enhanced patient compliance
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and varying regulatory environments across different countries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. BREO Ellipta Drugs Market, by Disease Condition

  • 6.1. Introduction
  • 6.2. Asthma
  • 6.3. COPD

7. BREO Ellipta Drugs Market, by Component

  • 7.1. Introduction
  • 7.2. Corticosteroid (ICS)
  • 7.3. Long-Acting Beta2-Adrenergic Agonist

8. BREO Ellipta Drugs Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals

9. BREO Ellipta Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Sales
  • 9.3. Pharmacies

10. Americas BREO Ellipta Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific BREO Ellipta Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa BREO Ellipta Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Iconovo's development of inhaled GLP-1 receptor agonists options
    • 13.3.2. FDA expands Breo Ellipta approval to children aged 5-17 for asthma maintenance
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca plc
  • 2. Boehringer Ingelheim International GmbH
  • 3. CHIESI Farmaceutici S.p.A.
  • 4. Cipla Limited
  • 5. GlaxoSmithKline plc
  • 6. Hikma Pharmaceuticals PLC
  • 7. Lupin Pharmaceuticals, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Orion Corporation
  • 11. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BREO ELLIPTA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BREO ELLIPTA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREO ELLIPTA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREO ELLIPTA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CORTICOSTEROID (ICS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LONG-ACTING BETA2-ADRENERGIC AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023